2. Search Result
Search Result
Results for "

intravenous injection

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

2

MCE Kits

1

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B2227B
    Lactate sodium
    Maximum Cited Publications
    8 Publications Verification

    Lactic acid sodium

    		 Bacterial Metabolic Disease Cancer
    Lactate (Lactic acid) sodium is the product of glycogenolysis and glycolysis . Lactate (Lactic acid) sodium is an organic salt that is mainly used as a buffer and pH adjuster for injection solutions. Lactate sodium can be metabolized by the body into sodium bicarbonate, which in turn acts to increase the pH of the blood. Lactate sodium is used to improve metabolic acidosis and hypovolemic states. In terms of pharmaceutical preparations, Lactate sodium is often used in combination with sodium chloride, glucose, etc. to form normal saline or compound liquid intravenous injection . Lactate sodium also has antimicrobial activity, which can be used as a food preservative .
    Lactate sodium
  • HY-N10225
    Thielavin A

    		Prostaglandin Receptor Cardiovascular Disease Endocrinology
    Thielavin A is an inhibitor of prostaglandin biosynthesis produced by Thielavia terricola. Thielavin A specifically inhibits the conversion of arachidonic acid into prostaglandin H2. Thielavin A has no anti-inflammatory activity on intravenous injection or on oral administration .
    Thielavin A
  • HY-B1657
    Fosphenytoin

    		Others Neurological Disease
    Fosphenytoin is a phosphate ester proagent developed as an alternative to intravenous phenytoin for acute intervention of seizures. Fosphenytoin has advantages including more convenient and rapid intravenous administration, availability for intramuscular injection, and low potential for adverse local reactions at injection sites .
    Fosphenytoin
  • HY-105236
    (Rac)-Enadoline

    (Rac)-CI-977 free base

    		 Opioid Receptor Neurological Disease
    (Rac)-Enadoline ((Rac)-CI-977 free base) is a selective K-opioid receptor agonist that stereoselectively antagonizes clonic seizures induced by slow intravenous injection of N-methyl-DL-aspartate in mice .
    (Rac)-Enadoline
  • HY-B1300A
    Cefonicid

    		Others Others
    Pharmacokinetic studies of Cefonicid have shown that high blood concentrations can be achieved rapidly after intravenous and intramuscular injection, and that concomitant use of albendazole prolongs its half-life in the body and reduces the rate of renal excretion .
    Cefonicid
  • HY-105919
    Naroparcil

    		Factor Xa Cardiovascular Disease
    Naroparcil is an orally active antithrombotic agent. Naroparcil exhibits antithrombotic effects in rabbit Wessler stasis model with EC50s of 21.9 mg/kg and 36.0 mg/kg after respectively intravenous injection and oral administration .
    Naroparcil
  • HY-B1300B
    Cefonicid monosodium

    		Others Others
    Pharmacokinetic studies of Cefonicid monosodium have shown that high blood concentrations can be achieved rapidly after intravenous and intramuscular injection, and that concomitant use of albendazole prolongs its half-life in the body and reduces the rate of renal excretion .
    Cefonicid monosodium
  • HY-106258
    Atilmotin

    OHM 11638; BAX-ACC 1638; MOT 288

    		 Motilin Receptor Metabolic Disease
    OHM 11638 (Atilmotin), an analogue of the (1-14) fragment of porcine motilin, is a motilin receptor agonist with a pKd of 8.94 for the motilin receptor. OHM 11638 affects esophageal, lower esophageal sphincter (LES), and gastric motility. OHM 11638 increases LES and gastric pressures, OHM 11638 can be used as prokinetic agents .
    Atilmotin
  • HY-130522
    6β-Prostaglandin I1

    6β-PGI1

    		 Others Others
    6β-Prostaglandin I1 (6β-PGI1) is an analog of prostaglandin I2 (PGI2) that is resistant to hydrolysis in aqueous solutions. 6β-Prostaglandin I1 can reduce gastric acid secretion with an ID50 (dose causing 50% inhibition) of approximately 3.0 μg/kg/min (intravenous injection) .
    6β-Prostaglandin I1
  • HY-B2227BR
    Lactate (sodium) (Standard)

    		Bacterial Metabolic Disease Cancer
    Lactate (sodium) (Standard) is the analytical standard of Lactate (sodium). This product is intended for research and analytical applications. Lactate (Lactic acid) sodium is the product of glycogenolysis and glycolysis . Lactate (Lactic acid) sodium is an organic salt that is mainly used as a buffer and pH adjuster for injection solutions. Lactate sodium can be metabolized by the body into sodium bicarbonate, which in turn acts to increase the pH of the blood. Lactate sodium is used to improve metabolic acidosis and hypovolemic states. In terms of pharmaceutical preparations, Lactate sodium is often used in combination with sodium chloride, glucose, etc. to form normal saline or compound liquid intravenous injection [4] . Lactate sodium also has antimicrobial activity, which can be used as a food preservative .
    Lactate (sodium) (Standard)
  • HY-137500
    NT1-014B

    		Liposome Neurological Disease
    NT1-014B is a potent NT1-lipidoid encapsulated AmB (amphotericin B). NT1-014B dopes the NT-lipidoids into BBB-impermeable lipid nanoparticles (LNPs) gave the LNPs the ability to cross the BBB. NT1-014B enhances brain delivery through intravenous injection .
    NT1-014B
  • HY-118350
    FR 75513

    		Others Neurological Disease
    FR 75513 is a 1,1'-biphenyl-2,6-dicarboxylic acid diester series compound that can inhibit the contraction of the detrusor muscle of guinea pig bladder (IC50=3.3 μg/mL). After intravenous injection of FR 75513 into anesthetized rats, it also showed strong inhibitory activity on the detrusor contraction (ID50=0.04 mg/kg).
    FR 75513
  • HY-106720C
    (+)-Amosulalol

    (+)-YM 09538

    		 Adrenergic Receptor Others
    (+)-Amosulalol ((+)-YM 09538) is an α,β-blocker with pharmacokinetic and metabolic activities in mice. In mice, the plasma concentration of (+)-Amosulalol decreased in a biphasic manner after intravenous injection. The time to reach the maximum plasma concentration after oral administration was 0.25h, and then decreased. The systemic bioavailability was 38.7%, and it was mainly excreted through urine. Multiple metabolites were detected in urine, and a new metabolite amosulalol carbamoyl glucuronide was found in bile samples.
    (+)-Amosulalol
  • HY-106720B
    (-)-Amosulalol

    (-)-YM 09538

    		 Adrenergic Receptor Others
    (-)-Amosulalol ((-)-YM 09538) is an α,β-blocker with pharmacokinetic and metabolic activities in mice. In mice, the plasma concentration of (-)-Amosulalol decreased in a biphasic manner after intravenous injection. The time to reach the maximum plasma concentration after oral administration was 0.25h, and then decreased. The systemic bioavailability was 38.7%, and it was mainly excreted through urine. Multiple metabolites were detected in urine, and a new metabolite amosulalol carbamoyl glucuronide was found in bile samples.
    (-)-Amosulalol
  • HY-12976
    DS-1558

    		G Protein-coupled Receptor Kinase (GRK) Metabolic Disease
    DS-1558 is an orally active small molecule G protein-coupled receptor 40 agonist. DS-1558 not only increases the glucose-stimulated insulin secretion by glucagon like peptide-1 (GLP-1) but also potentiated the maximum insulinogenic effects of GLP-1 after an intravenous glucose injection in normal Sprague Dawley rats. DS-1558 is promising for research of type 2 diabetes .
    DS-1558
  • HY-P0093
    Sincalide
    3 Publications Verification

    Cholecystokinin octapeptide; CCK-8; SQ19844

    		 Cholecystokinin Receptor Apoptosis PI3K Akt Infection Cancer
    Sincalide (Cholecystokinin octapeptide, CCK‐8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. CCK‐8 can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK .
    Sincalide
  • HY-P0093A
    Sincalide ammonium
    3 Publications Verification

    Cholecystokinin octapeptide ammonium; CCK-8 ammonium; SQ19844 ammonium

    		 Cholecystokinin Receptor Apoptosis PI3K Akt Infection Cancer
    Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. Sincalide ammonium can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK .
    Sincalide ammonium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: